Currently, the optimal antithrombotic therapy after transcatheter aortic valve replacement
(TAVR) remains still unknown., The purpose of the study is to compare aspirin versus
clopidogrel monoantiplatelet therapy for preventive effect on leaflet thrombosis in patients
undergoing TAVR for severe aortic stenosis. This study is designed as a prospective,
multicenter, open label, randomized controlled study. Eligible patients will be randomized to
aspirin or clopidogrel monotherapy after TAVR. Patients will have dual antiplatelet therapy
of aspirin 100 mg and clopidogrel 75 mg for 4 weeks after TAVR and then subsequent
monoantiplatelet therapy of either aspirin 100 mg or clopidogrel 75 mg according to the
randomization. Leaflet thrombosis will be assessed with cardiac computed tomography (CT) and
transthoracic echocardiography at 3 months after TAVR. Patients will be clinically followed
for 6 months. The primary endpoint is the Incidence of leaflet thrombosis on cardiac CT at 3
months.